tetano
Editor, Senior Moderator
Vaccine. 2014 Aug 6. pii: S0264-410X(14)01046-9. doi: 10.1016/j.vaccine.2014.07.079. [Epub ahead of print]
Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine.
Uraki R1, Das SC2, Hatta M2, Kiso M1, Iwatsuki-Horimoto K1, Ozawa M3, Coban C4, Ishii KJ5, Kawaoka Y6.
Author information
Abstract
Because vaccination is an effective means to protect humans from influenza viruses, extensive efforts have been made to develop not only new vaccines, but also for new adjuvants to enhance the efficacy of existing inactivated vaccines. Here, we examined the adjuvanticity of synthetic hemozoin, a synthetic version of the malarial by-product hemozoin, on the vaccine efficacy of inactivated whole influenza viruses in a mouse model. We found that mice immunized twice with hemozoin-adjuvanted inactivated A/California/04/2009 (H1N1pdm09) or A/Vietnam/1203/2004 (H5N1) virus elicited higher virus-specific antibody responses than did mice immunized with non-adjuvanted counterparts. Furthermore, mice immunized with hemozoin-adjuvanted inactivated viruses were better protected from lethal challenge with influenza viruses than were mice immunized with non-adjuvanted inactivated vaccines. Our results show that hemozoin improves the immunogenicity of inactivated influenza viruses, and is thus a promising adjuvant for inactivated whole virion influenza vaccines.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Adjuvant; Antibody; Hemozoin; Influenza virus; Vaccine
PMID:
25108216
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25108216
Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine.
Uraki R1, Das SC2, Hatta M2, Kiso M1, Iwatsuki-Horimoto K1, Ozawa M3, Coban C4, Ishii KJ5, Kawaoka Y6.
Author information
Abstract
Because vaccination is an effective means to protect humans from influenza viruses, extensive efforts have been made to develop not only new vaccines, but also for new adjuvants to enhance the efficacy of existing inactivated vaccines. Here, we examined the adjuvanticity of synthetic hemozoin, a synthetic version of the malarial by-product hemozoin, on the vaccine efficacy of inactivated whole influenza viruses in a mouse model. We found that mice immunized twice with hemozoin-adjuvanted inactivated A/California/04/2009 (H1N1pdm09) or A/Vietnam/1203/2004 (H5N1) virus elicited higher virus-specific antibody responses than did mice immunized with non-adjuvanted counterparts. Furthermore, mice immunized with hemozoin-adjuvanted inactivated viruses were better protected from lethal challenge with influenza viruses than were mice immunized with non-adjuvanted inactivated vaccines. Our results show that hemozoin improves the immunogenicity of inactivated influenza viruses, and is thus a promising adjuvant for inactivated whole virion influenza vaccines.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Adjuvant; Antibody; Hemozoin; Influenza virus; Vaccine
PMID:
25108216
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25108216